卫宁健康: 关于卫宁转债回售结果的公告

Core Viewpoint - The company announced the results of the convertible bond repurchase, indicating that no bonds were repurchased during the designated period, which will not significantly impact its financial status or operational capabilities [1][2]. Group 1: Announcement of Convertible Bond Repurchase - The company published multiple announcements regarding the repurchase of its convertible bonds, allowing holders to sell their bonds back to the company at a price of 100.281 CNY per bond, including interest and tax [1][2]. - The repurchase period was specified to end on May 16, 2025, after which the company would not need to process any payments to bondholders [2]. Group 2: Repurchase Results and Impact - The total number of valid repurchase applications for the "卫宁转债" was reported as 0, resulting in a repurchase amount of 0 CNY [2]. - The company stated that the lack of repurchase will not have a significant effect on its financial condition, operational results, cash flow, or capital structure, and it will not impair its debt servicing ability or ongoing operations [2].